NervGen Pharma has launched a new research initiative to advance its property therapeutic technology platform – currently in development for spinal cord injury and multiple sclerosis (MS) – to generate new treatments for Alzheimer’s disease (AD).
“NervGen’s platform technology provides an innovative approach to treating Alzheimer’s disease and has received positive affirmation from several Alzheimer’s disease key opinion leaders,” said Executive Chairman Bill Radvak.
“The essence of our technology is that it unlocks a damaged nervous system’s natural ability to repair itself and this could translate to helping people suffering from Alzheimer’s disease.”
Ernest Wong, President and CEO, confirmed that the company is “dedicated” to its clinical programme preparing its NVG-291 compound for a Phase 1a study due to commence in early 2020. This, he said, would be followed by a Phase 1b subsets of both chronic and sub-acute spinal cord patients and a Phase 2 study on MS.